QGEN Stock: Price, Earnings History and SEC Filings
Qiagen N.V. (QGEN) last traded at $50.22, down 0.24% on the latest session and up 14.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.62 against an analyst estimate of $0.60, a beat of 3.3%.
$50.22 -0.24%
1 month+14.76%
52-week high$57.82
52-week low$32.53
Volume4.17M
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
QGEN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.62 | $0.60 | +3.33% |
| Mar 2026 | May 6, 2026 | $0.54 | $0.54 | +0.00% |
| Dec 2025 | Feb 4, 2026 | $0.62 | $0.61 | +1.64% |
| Sep 2025 | Nov 4, 2025 | $0.64 | $0.61 | +4.92% |
QGEN beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for QGEN
SEC filing data is not available right now. You can search for QGEN on SEC EDGAR.
QGEN news
- Do Options Traders Know Something About Qiagen Stock We Don't?Oct 31, 2026 · finance.yahoo.com
- Qiagen (QGEN) On Its €9.7b Takeover Deal Still Looks Fully ValuedOct 31, 2026 · finance.yahoo.com
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGENOct 30, 2026 · finance.yahoo.com
- Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AIOct 30, 2026 · finance.yahoo.com
- Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex DiagnosticsOct 30, 2026 · finance.yahoo.com
- Global De Novo Genome Assembly Market 2026: Size, Share, Trends, and Forecast to 2030 | Capitalize on AI and Cloud Genomics with Illumina, PacBio, Oxford Nanopore, and QIAGENOct 30, 2026 · finance.yahoo.com
- Global Gene Panel Reconciliation Services Market Report 2026 | Capitalize on AI-Driven Genomics as Roche, Thermo Fisher, Illumina and QIAGEN Accelerate a $2.38B Market by 2030Oct 30, 2026 · finance.yahoo.com
- Global Reverse Transcription Kits Market Report 2026 | Capitalize on 8.4% CAGR as Roche, Thermo Fisher, Merck, QIAGEN and Promega Accelerate Automation and NGSOct 29, 2026 · finance.yahoo.com
About Qiagen N.V.
Qiagen N.V. (QGEN) is a US-listed public company on NYSE.